Finance

Beta
Lists
300147:SHE
Xiangxue Pharmaceutical Co Ltd
CNÂ¥9.58
+1.59%
(+0.15) 1D
Jun 10, 3:04:07 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 300147...
Open
CNÂ¥9.43
High
CNÂ¥9.79
Low
CNÂ¥9.26
Mkt. cap
6.24B
Avg. vol.
10.97M
Volume
9.69M
52-wk high
CNÂ¥12.79
52-wk low
CNÂ¥7.40
EPS
-CNÂ¥2.14
Shares outstanding
661.28M
No. of employees
3K
Open
CNÂ¥9.43
High
CNÂ¥9.79
Low
CNÂ¥9.26
Mkt. cap
6.24B
Avg. vol.
10.97M
Volume
9.69M
52-wk high
CNÂ¥12.79
52-wk low
CNÂ¥7.40
EPS
-CNÂ¥2.14
Shares outstanding
661.28M
No. of employees
3K
News stories
From sources across the web
Profile
Xiangxue Pharmaceutical Co., Ltd. also known as XPH, is a Chinese pharmaceutical company. It was headquartered in Guangzhou Economic and Technological Development Zone, Guangzhou, the capital of the Guangdong Province. The company started in a place that near to the tourist spot Luogang Xiangxue, thus called itself Xiangxue. Xiangxue Pharmaceutical was a constituent of SZSE 200 Index, but was removed in January 2017; it was inserted to SZSE 700 Index instead at the same time. SZSE 200, 300 and 700 Indexes are subsets of SZSE 1000 Index, the latter is a stock market index for the top 1,000 companies by free-float adjusted capitalization. In July 2017 Xiangxue was also removed from SZSE Component Index, an index for top 500 companies of the exchange. Wikipedia
About Xiangxue Pharmaceutical Co Ltd
CEO-
Employees2.66K
FoundedDec 29, 1997
Headquarters-
SectorPharmaceutical industry
Websitexphcn.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
396.99M
327.92M
449.49M
354.16M
Cost of goods sold
310.12M
176.35M
375.44M
228.49M
Cost of revenue
310.12M
176.35M
375.44M
228.49M
Research and development expenses
17.44M
15.40M
22.13M
10.74M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
116.81M
132.20M
75.98M
89.74M
Operating expense
136.85M
153.13M
96.02M
97.82M
Total operating expenses
446.96M
329.48M
471.45M
326.31M
Operating income
-49.98M
-1.56M
-21.96M
27.85M
Other non operating income
-2.20M
302.00K
-720.05M
-944.82K
EBT including unusual items
-138.23M
-118.29M
-1.00B
-89.20M
EBT excluding unusual items
-131.84M
-67.96M
-542.04M
-40.82M
Income tax expense
-640.89K
3.13M
30.08M
9.14M
Effective tax rate
0.46%
-2.65%
-3.00%
-10.25%
Other operating expenses
3.76M
3.55M
-37.47K
-3.18M
Net income
-146.14M
-128.03M
-1.03B
-111.44M
Net profit margin
-36.81%
-39.04%
-229.21%
-31.47%
Earnings per share
-
-
-
-
Interest and investment income
-
-
200.59M
23.18K
Interest expense
-79.66M
-66.70M
-619.18K
-67.75M
Net interest expenses
-79.66M
-66.70M
199.97M
-67.73M
Depreciation and amortization charges
-
-
-
-
EBITDA
7.84M
52.99M
25.60M
-
Gain or loss from assets sale
-932.06K
932.06K
-8.92M
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more